Menu

Xenotransplant Record

A donor heart from a genetically modified pig survives for more than 2.5 years inside a baboon’s abdomen.

Apr 6, 2016
Tanya Lewis

FLICKR, TITANIUM22Scientists have made an important stride toward pig-to-human xenotransplants: a heart from a genetically modified pig implanted in a baboon has survived for more than 2.5 years, thanks to a cocktail of anti-rejection drugs, researchers at the US National Institutes of Health reported yesterday (April 5) in Nature Communications. The researchers previously reported a survival record of 500 days for such a transplant.

“Xenotransplants—organ transplants between different species—could potentially save thousands of lives each year that are lost due to a shortage of human organs for transplantation,” study coauthor Muhammad Mohiuddin, a transplant surgeon at the National Heart, Lung, and Blood Institute, told the Agence France-Presse.

Previous efforts failed because the recipient’s immune system rejected the organs. To overcome this, Mohiuddin and colleagues used organs from knockout pigs that lacked the galactosyltransferase gene. This gene produces the human proteins CD46 and thrombomodulin, which prevent immune rejection and blood clotting, respectively.

The researchers transplanted the pig hearts into the abdomens of five baboons, and then treated the animals with a cocktail of anti-rejection drugs and antibodies, The Washington Post reported. The addtional, donor hearts survived for a median of 298 days inside the baboons, and one survived a record 945 days, the researchers reported. One animal had to be euthanized because of an infection.

“These hearts could have gone even longer, but we wanted to test to see if the animals had developed some kind of tolerance to the organs,” Mohiuddin told The Verge. When the researchers stopped administering the drug cocktail, the animals started to reject the organs, so they were removed, Mohiuddin explained.

The next step will be replacing the baboons’ own hearts with the pig organs, the researchers say. More research is needed before the procedure can be safely attempted in humans. Beyond rejection, there are concerns that humans could become infected with endogenous pig viruses. But Arthur Caplan, a bioethicist at New York University, told The Verge, “We have new gene editing techniques that will lets us focus on their immune system, so it should be possible to do it.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
INTEGRA has responded to customers’ requests and developed two new 24-channel pipetting heads, extending the capabilities of its popular VIAFLO 96/384.
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.